Searched for
DRL Q2
'Factually incorrect': Dr Reddy's denies 25% workforce cost reduction claimDr. Reddy's Laboratories has refuted a media report alleging a significant workforce cost reduction initiative. The report claimed the comp...- Dr Reddy's Labs Q2 Results: Profit falls 15% YoY to Rs 1,255 crore, revenue up 17%Dr Reddy's Labs Q2 Results: Healthcare major Dr Reddy's on Tuesday reported 15% drop in its consolidated net profit at Rs 1255 crore in the...
- Dr Reddy’s shares tumble 5% as Q4 numbers fail to impress analysts. Should you buy, sell or hold?Dr Reddy’s Share Price: The company said that the jump in YoY net profit was largely driven by growth in global generics revenues in North ...
- Dr Reddy's Labs Q2 Results: Profit rises 33% YoY to Rs 1,480 crore, revenue up 9%The company reported an EBITDA of Rs 2,181 crore in the September quarter, higher by 13% YoY. EBITDA margins in the same period came in at ...
- Dr Reddy's Q3 Results: PAT jumps 77% YoY to Rs 1,247 crore, beats estimatesAn ET Now poll had showed that analysts were expecting PAT at Rs 910 crore and revenue at Rs 5,830 crore.
- Dr Reddy’s Q2 Results: Profit jumps 12% YoY to Rs 1,114 crore; revenue rises 9.4%Consolidated earnings before interest, taxes, depreciation and amortization (EBITDA) for the quarter rose about 40% on year to Rs 1,899 cro...
- Dr Reddy’s Q2 Preview: High base to play spoilsport, outlook for US, Russia in focusDr Reddy’s topline will continue to be aided by sales contributions from the cancer drug Revlimid’s generic. While the overall revenue grow...
- DRL Q3 Results Preview: Profit may grow 25% YoY; margin likely to fallEdelweiss sess profit rising 26.5 per cent YoY to Rs 780 crore. It sees sales rising 12.2 per cent YoY to Rs 5,531 crore. The brokerage see...
- Dr Reddy’s Q2 results: Consolidated PAT rises 30% YoY, beats estimateThe drugmaker reported an 18 per cent on-year rise in consolidated revenues to Rs. 5,763 crore for the reported quarter, which also beat St...
- DRL, Cipla’s healthy outlook offsets Q4 slip, will help retain investor interestFor DRL, the US business failed to generate growth compared to the previous year partly due to high base effect as well as price erosion. I...
- Reduce Dr. Reddy's Laboratories, target Rs 2,759: Elara CapitalDr. Reddy's Laboratories is a largecap company, operating in pharmaceuticals and health care sector.
- Siddhartha Khemka of MOFSL is bullish on these 3 corporate banksMetal packs have been the single biggest drivers of Nifty earnings for the quarter, says Khemka
- DRL posts 77% jump in Q2 profit at Rs 504 crore, beats Street estimatesThe company had reported Rs 284.90 croe profit in the yer-ago quarter.
- Cipla, Dr Reddy’s Q4 results today; here’s what to expectPharma firms are expected to report double-digit rise in bottomline figures.
- Dr Reddy’s, feeling the pain now, looks better from long-term viewThe 'sell' recommendations on the stock more than doubled from 7 to 17 with leading brokerages downgrading the stock.
- Dr Reddy's Laboratories posts 76% jump in Q2 net profit at Rs 690 croreGeneric revenues from North America was up 43 per cent at Rs 1,324 crore during the quarter, as against Rs 927 crore in the year-ago period.
- Brokerages maintain 'hold' on Dr Reddy's post resultsShares of Dr Reddy’s Laboratories (DRL) were down on profit booking after the company disappointed the street with its quarterly results ye...
- Dr Reddy's Labs: Stock presents a high-risk, high-growth bet for investorsDr Reddys Labs' fourth quarter results were better than expected. The market responded positively to this with the stock closing higher at ...
- DRL net dips 68% on price pressure, writedownDr Reddy’s Laboratories (DRL) suffered a 68% fall in Q4 net profit ended March 2008, after writing down the intangible value of the product...
- DRL plans to launch 200 generics in USPharma major Dr Reddy’s Labs is planning to storm the US generics market by launching around 200 products over the next five years.
Load More
